NCT06066580
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Enrolling by Invitation
PHASE2All AgesInterventionalTreatmentEdgewise Therapeutics, Inc.
~260 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:Sevasemten
At a glance
Recruiting sites
0 of 46 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of adverse events in those treated with sevasemten
Measured over 55 Months
+1 more outcome measured
Conditions
Where it's being run
46 sites across 27 statesCalifornia5
France4
Spain4
United Kingdom4
Belgium3
Italy3
Ohio2
Texas2
Study leadership
- Joanne M. Donovan, MD, PhD · STUDY_CHAIR · Edgewise Therapeutics, Inc.
- Roxana D. Dreghici, MD · STUDY_CHAIR · Edgewise Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
EDG-5506-002 ARCH: Complete the final study Visit 27 \[Month 24\]; or, completion of the ET visit prior to Visit 27 \[Month 24\]
EDG-5506-201 CANYON and GRAND CANYON: Complete the final study visit (Cohorts 1, 2, 4, and 5: Visit 12 \[Month 12\]; Cohort 6: Visit 11 \[Month 18\])
EDG-5506-202 DUNE: Complete at least 36 weeks of open-label treatment (Visit 14 \[Week 52\])
What this trial measures
- Number of adverse events in those treated with sevasemten55 Months
- Severity of adverse events in those treated with sevasemten55 Months